Insulet Corp (NAS:PODD)
$ 199.42 2.91 (1.48%) Market Cap: 13.97 Bil Enterprise Value: 14.41 Bil PE Ratio: 60.40 PB Ratio: 17.65 GF Score: 84/100

Insulet Corp at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 07:00PM GMT
Release Date Price: $185.26 (+0.44%)
Robert Justin Marcus
JP Morgan Chase & Co, Research Division - Analyst

Hello everybody, I'm Robbie Marcus, the medical device analyst at JPMorgan. I'm very pleased to introduce Shacey Petrovic, the President and CEO of Insulet.

Shacey?

Shacey Petrovic
Insulet Corporation - President, CEO & Director

Thanks, Robbie. It's great to be here this morning to discuss Insulet Corporation. Our mission at Insulet is to improve the lives of people living with insulin-dependent diabetes. And in fact, I grew up with diabetes in my family. My father has lived with type 1 for more than 40 years now.

For most of his life, he was pretty poorly controlled on multiple daily injections. And I always think of him when I see this picture of Lexi. In 2015, he started to use Omnipod. It was a game changer for him. And like Lexi, my father is an avid swimmer. And he also goes to the gym quite frequently, and he needed a technology to sort of fit into his lifestyle. So you could see Omnipod here pictured on Lexi's arm. It's a 3-day disposable patch pump that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot